GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prothena Corp PLC (NAS:PRTA) » Definitions » Shiller PE Ratio

Prothena (Prothena) Shiller PE Ratio : (As of Jun. 11, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Prothena Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Prothena Shiller PE Ratio Historical Data

The historical data trend for Prothena's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prothena Shiller PE Ratio Chart

Prothena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Prothena Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Prothena's Shiller PE Ratio

For the Biotechnology subindustry, Prothena's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prothena's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prothena's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Prothena's Shiller PE Ratio falls into.



Prothena Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Prothena's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Prothena's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.34/120.9901*120.9901
=-1.340

Current CPI (Mar. 2024) = 120.9901.

Prothena Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.060 100.773 0.072
201409 -0.480 100.474 -0.578
201412 -0.480 99.576 -0.583
201503 -0.550 99.975 -0.666
201506 -0.590 100.573 -0.710
201509 -0.730 100.274 -0.881
201512 -0.760 99.676 -0.923
201603 -0.810 99.676 -0.983
201606 -1.180 101.072 -1.413
201609 -1.260 100.274 -1.520
201612 -1.410 99.676 -1.712
201703 -0.990 100.374 -1.193
201706 -0.460 100.673 -0.553
201709 -1.370 100.474 -1.650
201712 -1.240 100.075 -1.499
201803 -1.260 100.573 -1.516
201806 -1.500 101.072 -1.796
201809 -0.620 101.371 -0.740
201812 -0.560 100.773 -0.672
201903 -0.520 101.670 -0.619
201906 -0.400 102.168 -0.474
201909 -0.490 102.268 -0.580
201912 -0.540 102.068 -0.640
202003 -0.590 102.367 -0.697
202006 -0.660 101.769 -0.785
202009 -0.770 101.072 -0.922
202012 -0.770 101.072 -0.922
202103 -0.910 102.367 -1.076
202106 0.580 103.364 0.679
202109 2.130 104.859 2.458
202112 -0.710 106.653 -0.805
202203 -0.780 109.245 -0.864
202206 -0.880 112.779 -0.944
202209 -0.970 113.504 -1.034
202212 0.120 115.436 0.126
202303 -0.890 117.609 -0.916
202306 -1.030 119.662 -1.041
202309 0.380 120.749 0.381
202312 -1.260 120.749 -1.263
202403 -1.340 120.990 -1.340

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Prothena  (NAS:PRTA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Prothena Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Prothena's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Prothena (Prothena) Business Description

Traded in Other Exchanges
Address
77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, IRL, D02 VK60
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Executives
Karin L Walker officer: See Remarks C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Brandon S. Smith officer: Chief Operating Officer C/O PROTHENA BIOSCIENCES INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Carol D. Karp officer: Chief Regulatory Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Michael J Malecek officer: Chief Legal Officer C/O PROTHENA BIOSCIENCES, INC., 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hideki Garren officer: Chief Medical Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Wagner M. Zago officer: Chief Scientific Officer C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dennis J. Selkoe director 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Helen Susan Kim director 3832 BAY CENTER PLACE, HAYWARD CA 94545
Tran Nguyen officer: Chief Financial Officer C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Gene G. Kinney officer: CSO & Head of R&D C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Dunn William H. Jr. director C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Shane Cooke director TREASURY BUILDING LOWER GRAND CANAL ST., DUBLIN 2 L2 00000
Richard T Collier director
Lars Ekman director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Paula K Cobb director NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453